Jin and Billy Dunn were coauthors on a statistical analysis of Alzheimer's trial studies, and published together as recently as 2020.
This hire is a masterstroke by Missling. Not only is Jin the FDA's former lead expert on the Aduhelm submission, but he clearly has the professional trust and respect of the FDA's key decisionmaker, Billy Dunn. For all of you posters complaining that the FDA is corrupt and owned by Big Pharma -- move over, this is better. And cheaper, since Missling can pay in stock options instead of royalties.